vs
Side-by-side financial comparison of Creative Media & Community Trust Corp (CMCT) and Journey Medical Corp (DERM). Click either name above to swap in a different company.
Creative Media & Community Trust Corp is the larger business by last-quarter revenue ($28.5M vs $16.1M, roughly 1.8× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -125.8%, a 118.0% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 3.6%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -8.5%).
Creative Media & Community Trust Corp is a U.S.-headquartered real estate investment trust operating two core segments: it owns, manages and develops creative media facilities including professional film and TV production studios, plus community-focused assets such as affordable housing, neighborhood healthcare centers and local commercial spaces, serving media operators and local communities nationwide.
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
CMCT vs DERM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $28.5M | $16.1M |
| Net Profit | $-11.4M | $-1.2M |
| Gross Margin | — | — |
| Operating Margin | -125.6% | -2.8% |
| Net Margin | -125.8% | -7.8% |
| Revenue YoY | 3.6% | 27.3% |
| Net Profit YoY | -11.4% | -182.0% |
| EPS (diluted) | $-3.89 | $-0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $28.5M | $16.1M | ||
| Q3 25 | $26.2M | $17.0M | ||
| Q2 25 | $29.7M | $15.0M | ||
| Q1 25 | $32.3M | $13.1M | ||
| Q4 24 | $27.5M | $12.6M | ||
| Q3 24 | $28.6M | $14.6M | ||
| Q2 24 | $34.4M | $14.9M | ||
| Q1 24 | $34.0M | $13.0M |
| Q4 25 | $-11.4M | $-1.2M | ||
| Q3 25 | $-12.5M | $-2.3M | ||
| Q2 25 | $-9.0M | $-3.8M | ||
| Q1 25 | $-6.1M | $-4.1M | ||
| Q4 24 | $-10.3M | $1.5M | ||
| Q3 24 | $-10.4M | $-2.4M | ||
| Q2 24 | $-796.0K | $-3.4M | ||
| Q1 24 | $-3.7M | $-10.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 82.3% | ||
| Q3 24 | — | 63.9% | ||
| Q2 24 | — | 56.0% | ||
| Q1 24 | — | 47.7% |
| Q4 25 | -125.6% | -2.8% | ||
| Q3 25 | -47.7% | -9.0% | ||
| Q2 25 | -30.3% | -19.2% | ||
| Q1 25 | -19.0% | -25.3% | ||
| Q4 24 | -128.8% | 17.7% | ||
| Q3 24 | -36.9% | -19.8% | ||
| Q2 24 | -1.6% | -19.7% | ||
| Q1 24 | -10.7% | -77.4% |
| Q4 25 | -125.8% | -7.8% | ||
| Q3 25 | -47.5% | -13.6% | ||
| Q2 25 | -30.3% | -25.3% | ||
| Q1 25 | -18.9% | -31.0% | ||
| Q4 24 | -129.8% | 12.1% | ||
| Q3 24 | -36.3% | -16.3% | ||
| Q2 24 | -2.3% | -22.6% | ||
| Q1 24 | -11.0% | -80.1% |
| Q4 25 | $-3.89 | $-0.04 | ||
| Q3 25 | $-23.52 | $-0.09 | ||
| Q2 25 | $-18.94 | $-0.16 | ||
| Q1 25 | $-20.73 | $-0.18 | ||
| Q4 24 | $97.71 | $0.10 | ||
| Q3 24 | $-305.04 | $-0.12 | ||
| Q2 24 | $-98.64 | $-0.17 | ||
| Q1 24 | $-125.46 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $15.4M | $24.1M |
| Total DebtLower is stronger | $509.8M | $25.3M |
| Stockholders' EquityBook value | $265.4M | $31.9M |
| Total Assets | $859.2M | $94.6M |
| Debt / EquityLower = less leverage | 1.92× | 0.79× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.4M | $24.1M | ||
| Q3 25 | $17.3M | $24.9M | ||
| Q2 25 | $27.8M | $20.3M | ||
| Q1 25 | $19.8M | $21.1M | ||
| Q4 24 | $20.3M | $20.3M | ||
| Q3 24 | $18.5M | $22.5M | ||
| Q2 24 | $29.3M | $23.9M | ||
| Q1 24 | $21.3M | $24.1M |
| Q4 25 | $509.8M | $25.3M | ||
| Q3 25 | $527.8M | $25.2M | ||
| Q2 25 | $535.6M | $25.1M | ||
| Q1 25 | $512.7M | $25.0M | ||
| Q4 24 | $505.7M | $24.9M | ||
| Q3 24 | $478.3M | $19.8M | ||
| Q2 24 | $485.1M | $19.7M | ||
| Q1 24 | $472.8M | $14.7M |
| Q4 25 | $265.4M | $31.9M | ||
| Q3 25 | $281.9M | $25.9M | ||
| Q2 25 | $287.1M | $19.2M | ||
| Q1 25 | $293.0M | $21.5M | ||
| Q4 24 | $304.5M | $20.1M | ||
| Q3 24 | $321.0M | $10.9M | ||
| Q2 24 | $351.1M | $11.3M | ||
| Q1 24 | $369.9M | $13.0M |
| Q4 25 | $859.2M | $94.6M | ||
| Q3 25 | $871.8M | $85.2M | ||
| Q2 25 | $885.0M | $81.2M | ||
| Q1 25 | $882.3M | $85.0M | ||
| Q4 24 | $889.6M | $80.2M | ||
| Q3 24 | $868.0M | $64.0M | ||
| Q2 24 | $891.2M | $65.2M | ||
| Q1 24 | $887.5M | $66.6M |
| Q4 25 | 1.92× | 0.79× | ||
| Q3 25 | 1.87× | 0.97× | ||
| Q2 25 | 1.87× | 1.30× | ||
| Q1 25 | 1.75× | 1.16× | ||
| Q4 24 | 1.66× | 1.24× | ||
| Q3 24 | 1.49× | 1.81× | ||
| Q2 24 | 1.38× | 1.75× | ||
| Q1 24 | 1.28× | 1.13× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.8M | $-6.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.8M | $-6.3M | ||
| Q3 25 | $3.7M | $-2.4M | ||
| Q2 25 | $-2.5M | $-942.0K | ||
| Q1 25 | $1.2M | $-2.8M | ||
| Q4 24 | $17.0M | $2.2M | ||
| Q3 24 | $10.3M | $-1.2M | ||
| Q2 24 | $3.9M | $-5.2M | ||
| Q1 24 | $1.6M | $-5.0M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CMCT
Segment breakdown not available.
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
